Suggested remit: To appraise the clinical and cost effectiveness of pexidartinib within its marketing authorisation for treating symptomatic tenosynovial giant cell tumour.
Following on from information provided to NICE by the company in July 2020 the appraisal of Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1682
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 November 2022 | Note added to the project documents |
| 15 November 2022 | Discontinued. Following on from information provided to NICE by the company in July 2020 the appraisal of Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 02 October 2020 | Note added to the project documents |
| 02 October 2020 | Suspended. Topic has been suspended |
| 07 May 2020 | Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available. |
| 16 March 2020 (14:00) | Scoping workshop (Manchester) |
| 21 January 2020 - 18 February 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual